Trials / Recruiting
RecruitingNCT06590896
Safety of Cenobamate in Japanese Subjects With Partial Onset Seizures
A Phase 2, Multicenter Open-Label Extension Study to Evaluate the Long-term Safety of Cenobamate in Japanese Subjects With Partial Onset Seizures
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- Sponsor
- Ono Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
To evaluate the long-term safety and tolerability of cenobamate in Japanese epilepsy patients with partial seizures
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cenobamate | Cenobamate will be orally administered once daily. |
Timeline
- Start date
- 2022-11-04
- Primary completion
- 2027-01-31
- Completion
- 2027-01-31
- First posted
- 2024-09-19
- Last updated
- 2025-06-03
Locations
29 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT06590896. Inclusion in this directory is not an endorsement.